Sun Pharmaceutical Industries Ltd (SUNPHARMA) — Corporate Governance | 29 September 2026

29 September 2026 · BSE 🟡 Notable Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Board composition updated with new appointments and retirements effective September 2025 and May 2026.

🔄 What Changed

Board size increased to 8 directors with 4 independent members; 50% independent director requirement met; leadership transition from MD to Executive Chairman completed; ESG Committee formalized with board oversight.

🔮 What's Next

Board will continue to oversee ESG integration through the Corporate Governance & ESG Committee; succession planning remains active; no specific future governance targets disclosed.

💡 Investor Takeaway

Routine procedural filing with no direct impact on shareholders.

Sun Pharmaceutical Industries Ltd submitted its ESG Overview for FY 2025-26, detailing governance changes including board composition updates, committee structures, and compliance status. The filing highlights a 50% independent board, 95.24% meeting attendance, and key leadership transitions, such as Mr. Kirti Ganorkar appointed as Managing Director and Mr. Dilip Shanghvi retaining the Executive Chairman role. Environmental performance showed significant reductions in carbon and water usage, while social metrics included 17.97% female workforce representation. The report adheres to GRI standards and was externally assured by DNV.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹4,41,477.63 CrP/E: 36.5ROE: 14.5%ROCE: 18.7%Div Yield: 0.87%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How does the 50% independent board ratio compare to industry peers?""What is the expected impact of the new MD's compensation on profitability?""How will ESG targets be measured against financial performance?"

Ask AI Free →

📊 More SUNPHARMA filings

🔴 Announcement — 28 September 2026Sun Pharma announced a global licensing deal with LIB Therapeutics for lerodalcibep, a PCSK9 inhibit...
🟡 Voting Results — 28 September 2026Sun Pharmaceutical Industries announced the completion of its postal ballot dated 25 August 2026, co...
🟡 Shareholding Pattern — 26 September 2026Sun Pharmaceutical Industries announced that shareholders approved reclassifying the promoter group ...
Announcement — 25 September 2026Sun Pharmaceutical announces that its trading window will close on 1 October 2026 and remain shut un...
🔴 Announcement — 22 September 2026Sun Pharmaceutical Industries Limited presented its investor outlook for FY26, highlighting a divers...

See all SUNPHARMA filings →

🔥 Also filed on 29 September 2026

ADANIPOWERAdani Power LtdAnnouncement APOLLOApollo Micro Systems LtdAnnouncement ADANIENTAdani Enterprises LtdAnnouncement ADANIPORTSAdani Ports & Special Economic Zone LtdAnnouncement PFOCUSPrime Focus LtdAnnouncement MCXMulti Commodity Exchange of India LtdAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.